Vigil Neuroscience’s (VIGL) Buy Rating Reiterated at HC Wainwright

Vigil Neuroscience (NASDAQ:VIGL)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued on Friday, Benzinga reports. They currently have a $24.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 435.71% from the stock’s current price.

VIGL has been the subject of a number of other research reports. JMP Securities reaffirmed a “market outperform” rating and set a $23.00 price objective on shares of Vigil Neuroscience in a research report on Thursday, April 18th. Wedbush restated an “outperform” rating and set a $22.00 price target on shares of Vigil Neuroscience in a research report on Wednesday, May 8th.

Vigil Neuroscience Stock Performance

VIGL opened at $4.48 on Friday. The stock has a market capitalization of $168.36 million, a PE ratio of -2.11 and a beta of 1.94. Vigil Neuroscience has a one year low of $2.47 and a one year high of $10.22. The business’s 50 day moving average price is $3.49 and its 200 day moving average price is $3.31.

Vigil Neuroscience (NASDAQ:VIGL) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.10. As a group, equities research analysts forecast that Vigil Neuroscience will post -2.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vigil Neuroscience

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in shares of Vigil Neuroscience by 11.9% in the first quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock worth $3,050,000 after acquiring an additional 95,276 shares in the last quarter. PEAK6 Investments LLC boosted its holdings in Vigil Neuroscience by 66.0% in the third quarter. PEAK6 Investments LLC now owns 23,796 shares of the company’s stock valued at $128,000 after purchasing an additional 9,459 shares during the period. Finally, Strs Ohio acquired a new position in Vigil Neuroscience during the 4th quarter worth $27,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.